Radiation Therapy Quality Assurance In Clinical Trials

By Andrew Cowen, Chief Executive Officer, Radialogica LLC; Scott Brame, Ph.D., Chief Operating Officer, Radialogica LLC; David Alsadius, MD Ph.D., Senior Medical Director, Oncology Center of Excellence, IQVIA R&DS; Kimberly Clarke, Associate Director, Cell & Gene Therapy / Oncology Strategy, IQVIA Biotech; and Forrest Anthony, MD, Senior Medical Director, Oncology Center of Excellence, IQVIA R&DS

Radiation therapy (RT) remains a fundamental component of cancer treatment, frequently used in clinical trials to assess innovative systemic therapies in both curative and palliative settings. The advanced precision of RT allows for highly accurate treatment with reduced toxicity, provided it is administered correctly. Despite its benefits, the complexity involved in RT planning and delivery necessitates rigorous quality assurance to address practice variability, prevent suboptimal treatments, and ensure patient safety and treatment efficacy.

This white paper highlights the pivotal role of radiation therapy in cancer care and its importance in oncology clinical trials. It examines the sources of variability in RT that can impact outcomes and study results, and presents a comprehensive quality management program designed to enhance the implementation of RT in pharmaceutical trials. By addressing these critical aspects, the paper aims to improve the consistency and effectiveness of RT practices, ultimately advancing cancer treatment and research.